CD22 and systemic sclerosis: Patients with CD22 autoantibodies exhibit significantly worse skin scores than SSc patients without these antibodies and it is hypothesised that anti-CD22 autoantibodies are likely to interfere with CD22-mediated suppression of B cell activation, resulting in further dysregulation of B cell homeostasis (45).